このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

ReShape Lifesciences 将来の成長

Future 基準チェック /26

ReShape Lifesciencesは、36.4%と20.6%でそれぞれ年率36.4%で利益と収益が成長すると予測される一方、EPSはgrowで55.7%年率。

主要情報

36.4%

収益成長率

55.7%

EPS成長率

Medical Equipment 収益成長	16.7%
収益成長率	20.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	27 Nov 2023

今後の成長に関する最新情報

Recent updates

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

Apr 18

ReShape wins FDA clearance for device used in weight loss surgery

Aug 10

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Mar 31

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Dec 09

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Aug 24

業績と収益の成長予測

NasdaqCM:RSLS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	12	-6	N/A	N/A	1
12/31/2024	10	-7	N/A	N/A	1
3/31/2024	8	-11	-14	-14	N/A
12/31/2023	9	-11	-17	-17	N/A
9/30/2023	10	-26	-17	-17	N/A
6/30/2023	10	-35	-20	-20	N/A
3/31/2023	11	-41	-20	-20	N/A
12/31/2022	11	-46	-22	-22	N/A
9/30/2022	11	-66	-23	-22	N/A
6/30/2022	12	-72	-25	-25	N/A
3/31/2022	13	-66	-21	-21	N/A
12/31/2021	14	-63	-16	-15	N/A
9/30/2021	14	-35	-14	-14	N/A
6/30/2021	14	-22	-7	-7	N/A
3/31/2021	12	-22	-8	-7	N/A
12/31/2020	11	-22	-9	-9	N/A
9/30/2020	12	-38	-8	-8	N/A
6/30/2020	12	-62	-12	-11	N/A
3/31/2020	15	-74	-12	-12	N/A
12/31/2019	15	-74	-14	-14	N/A
9/30/2019	11	-52	-20	-20	N/A
6/30/2019	8	-28	-20	-20	N/A
3/31/2019	4	-35	-24	-24	N/A
12/31/2018	1	-38	-28	-27	N/A
9/30/2018	0	-42	-29	-29	N/A
6/30/2018	1	-47	-30	-30	N/A
3/31/2018	1	-30	-30	-29	N/A
12/31/2017	1	-30	N/A	-25	N/A
9/30/2017	1	-29	N/A	-19	N/A
6/30/2017	1	-25	N/A	-18	N/A
3/31/2017	1	-23	N/A	-18	N/A
12/31/2016	1	-23	N/A	-21	N/A
9/30/2016	1	-26	N/A	-22	N/A
6/30/2016	1	-23	N/A	-24	N/A
3/31/2016	0	-26	N/A	-24	N/A
12/31/2015	0	-25	N/A	-23	N/A
9/30/2015	0	-25	N/A	-22	N/A
6/30/2015	0	-26	N/A	-20	N/A
3/31/2015	N/A	-27	N/A	-19	N/A
12/31/2014	N/A	-26	N/A	-19	N/A
9/30/2014	N/A	-27	N/A	-19	N/A
6/30/2014	N/A	-27	N/A	-19	N/A
3/31/2014	N/A	-26	N/A	-19	N/A
12/31/2013	N/A	-26	N/A	-18	N/A
9/30/2013	N/A	-26	N/A	-20	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RSLS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RSLS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: RSLS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: RSLSの収益 ( 20.6% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: RSLSの収益 ( 20.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RSLSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

ReShape Lifesciences 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to US$3.84 loss, revenue downgraded

Consensus revenue estimates decrease by 23%, EPS upgraded

Consensus EPS estimates upgraded to US$5.85 loss, revenue downgraded

Consensus EPS estimates upgraded to US$16.50 loss

Consensus revenue estimates fall by 16%

ReShape Lifesciences Inc. Provides Revenue Guidance

Recent updates

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q1, 2024 Results on May 15, 2024

The Nasdaq Stock Market Determines ReShape Lifesciences Eligible for an Additional 180 Calendar Period, or Until October 7, 2024, to Regain Compliance with Minimum Bid Price Requirement

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System

Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

Consensus EPS estimates upgraded to US$3.84 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q3, 2023 Results on Nov 08, 2023

ReShape Lifesciences Receives Non-Compliance Notice From Nasdaq

ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device

Consensus revenue estimates decrease by 23%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReShape Lifesciences Inc. to Report Q2, 2023 Results on Aug 07, 2023

ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting

ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0

Consensus EPS estimates upgraded to US$5.85 loss, revenue downgraded

ReShape Lifesciences Inc. to Report Q1, 2023 Results on May 15, 2023

Consensus EPS estimates upgraded to US$16.50 loss

Full year 2022 earnings: EPS misses analyst expectations

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

Consensus revenue estimates fall by 16%

ReShape Lifesciences Inc. Provides Revenue Guidance

Price target decreased to US$1.03

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$1.48 loss in 3Q 2021)

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

ReShape Lifesciences Inc. to Report Q3, 2022 Results on Nov 14, 2022

Reshape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®

ReShape Lifesciences Announces Release of Positive Consensus Statement on Lap-Band Use and Lap-Band Aftercare Management by American Society of Metabolic and Bariatric Surgery

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

ReShape Lifesciences Inc. announced delayed 10-Q filing

Price target decreased to US$3.08

Insufficient new directors

Reshape Lifesciences™ Receives FDA 510(K) Clearance for the Gibi Hd™ Calibration Tubes for Use in Gastric and Bariatric Procedures

ReShape wins FDA clearance for device used in weight loss surgery

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

ReShape Lifesciences Receives Non-Compliance Notice from Nasdaq

ReShape Lifesciences Inc. to Report Q1, 2022 Results on May 23, 2022

ReShape Lifesciences Inc. announced delayed 10-Q filing

ReShape Lifesciences Inc. announced delayed annual 10-K filing

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$0.74 loss in 3Q 2020)

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Second quarter 2021 earnings released: US$0.47 loss per share (vs US$0.52 loss in 2Q 2020)

High number of new directors

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$12.00

ReShape Lifesciences Inc. (OTCPK:RSLS) completed the acquisition of Obalon Therapeutics, Inc. (NasdaqCM:OBLN) in a reverse merger transaction.

ReShape Lifesciences Inc. (OTCPK:RSLS) entered into an agreement to acquire Obalon Therapeutics, Inc. (NasdaqCM:OBLN).

ReShape Lifesciences Inc. to Report Q2, 2020 Results on Aug 13, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘